Overview

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Olaparib
Paclitaxel
Poly(ADP-ribose) Polymerase Inhibitors